AVI Biopharma, (NASDAQ: [[ticker:AVII]]) a Portland, OR-based developer of drugs using RNA interference technology, said today it has hired J. David Boyle II as chief financial officer, while current CFO Mark Webber will become general manager of finance and administration. Alan Timmins, the current president and chief operating officer, will leave the company and his duties as president will be assumed by CEO Leslie Hudson.
Author: Luke Timmerman
Luke is an award-winning journalist specializing in life sciences. He has served as national biotechnology editor for Xconomy and national biotechnology reporter for Bloomberg News. Luke got started covering life sciences at The Seattle Times, where he was the lead reporter on an investigation of doctors who leaked confidential information about clinical trials to investors. The story won the Scripps Howard National Journalism Award and several other national prizes. Luke holds a bachelor’s degree in journalism from the University of Wisconsin-Madison, and during the 2005-2006 academic year, he was a Knight Science Journalism Fellow at MIT.
View all posts by Luke Timmerman
